GO:0018108 peptidyl-tyrosine phosphorylation: Signaling Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0018108 peptidyl-tyrosine phosphorylation is the biological process that attaches a phosphate group to tyrosine residues on proteins, forming peptidyl-O4'-phospho-L-tyrosine.
• This modification is a central switch in intracellular signal transduction and is frequently dysregulated in cancer, metabolic disease, and neurodegeneration.
• Key enzymes include tyrosine kinases such as FGF receptors, and phosphatases such as PTPN1 that remove the phosphate and terminate signaling.
• Plasma proteomic studies link tyrosine-phosphorylation-related proteins to cardiovascular health and incident dementia in large cohorts.
• Mendelian randomization and bioinformatics analyses have implicated FGF5 and related tyrosine kinase pathways in stroke risk.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of tyrosine phosphorylation genes in disease.
Description
Peptidyl-tyrosine phosphorylation (GO:0018108) is a post-translational modification in which a phosphate group is covalently added to the hydroxyl group of a tyrosine residue within a protein, generating peptidyl-O4'-phospho-L-tyrosine. This process is a fundamental mechanism of cellular signal transduction and is catalyzed by protein tyrosine kinases, while protein tyrosine phosphatases reverse the modification. Because tyrosine phosphorylation controls enzyme activity, protein-protein interactions, and subcellular localization, it is essential for proliferation, differentiation, migration, and survival. Dysregulation of this process is a hallmark of many human diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions. Large-scale proteomic and genetic studies have repeatedly identified tyrosine-phosphorylation-related proteins as biomarkers and causal candidates in disease. For researchers, GO:0018108 provides a structured framework to annotate and interrogate signaling events, and CRISPR-based models now allow precise functional testing of the genes that carry out this modification.
peptidyl-tyrosine phosphorylation At A Glance
| GO ID | GO:0018108 |
|---|---|
| GO term | peptidyl-tyrosine phosphorylation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Covalent addition of phosphate to tyrosine residues, enabling signal transduction and protein interaction |
| Enzyme class | Protein tyrosine kinases (writers) and protein tyrosine phosphatases (erasers) |
| Representative kinases | FGF receptor family, and other receptor/non-receptor tyrosine kinases |
| Representative phosphatases | PTPN1 and related protein tyrosine phosphatases |
| Disease relevance | Cancer, cardiovascular disease, stroke, and dementia |
| Research methods | Bioinformatics, proteomics, Mendelian randomization, CRISPR models |
What Is GO:0018108?
According to the Gene Ontology, GO:0018108 peptidyl-tyrosine phosphorylation is defined as the phosphorylation of peptidyl-tyrosine to form peptidyl-O4'-phospho-L-tyrosine. In practical terms, it is the enzymatic transfer of a phosphate group from ATP to the side-chain hydroxyl of a tyrosine residue in a polypeptide, producing a phosphotyrosine moiety that can recruit SH2-domain-containing proteins and propagate intracellular signals.
Why Is peptidyl-tyrosine phosphorylation Important in Cell Biology?
Peptidyl-tyrosine phosphorylation is one of the most important regulatory modifications in eukaryotic cells because it converts extracellular and intracellular cues into coordinated changes in cell behavior. It is the defining activity of tyrosine kinases, a protein family that includes major drug targets in oncology, and its reversal by phosphatases provides a dynamic on/off switch. Because phosphotyrosine signals control proliferation, survival, and migration, their dysregulation contributes directly to cancer, metabolic disorders, and neurodegeneration. Consequently, mapping and manipulating this process is central to both basic discovery and therapeutic development.
• Controls intracellular signal transduction from receptor tyrosine kinases to downstream effectors.
• Regulates cell proliferation, differentiation, migration, and survival.
• Is reversibly controlled by protein tyrosine phosphatases such as PTPN1.
• Is implicated in cancer through altered kinase and phosphatase activity.
• Is linked to cardiovascular health and incident dementia in large proteomic cohorts.
• Is associated with stroke risk through FGF5-related pathways in Mendelian randomization.
• Provides biomarkers for bladder cancer and glioma through bioinformatics analyses.
• Enables CRISPR-based causal testing of signaling genes in disease models.
• Supports drug discovery targeting tyrosine kinase pathways.
• Underpins precision medicine strategies that stratify patients by phospho-signaling profiles.
What Happens During peptidyl-tyrosine phosphorylation?
Recognition of substrate tyrosine residues
In simple terms: The kinase first finds the right tyrosine on the right protein.
Protein tyrosine kinases recognize specific sequence and structural contexts around target tyrosine residues, allowing selective phosphorylation of substrates within signaling networks. This selectivity is essential because inappropriate phosphorylation can drive disease, and bioinformatics analyses have identified tyrosine-phosphorylation-related genes as core biomarkers in cancer.
Phosphate transfer from ATP
In simple terms: The kinase moves a phosphate from ATP onto the tyrosine.
The catalytic domain of a tyrosine kinase transfers the gamma-phosphate of ATP to the hydroxyl group of peptidyl-tyrosine, forming peptidyl-O4'-phospho-L-tyrosine. This covalent modification creates a docking site for SH2 and PTB domain proteins that propagate the signal.
Assembly of phosphotyrosine-dependent complexes
In simple terms: The new phosphotyrosine acts like a plug that recruits partner proteins.
Once formed, phosphotyrosine motifs recruit effector proteins that contain phosphotyrosine-binding domains, leading to activation of downstream pathways such as MAPK, PI3K-AKT, and STAT signaling. These complexes determine the cellular outcome of the signal and are frequently rewired in cancer.
Signal termination by tyrosine phosphatases
In simple terms: Phosphatases remove the phosphate to switch the signal off.
Protein tyrosine phosphatases such as PTPN1 hydrolyze the phosphotyrosine bond, reversing the modification and terminating or reshaping the signal. The balance between kinase and phosphatase activity determines the amplitude and duration of tyrosine phosphorylation events.
Integration with disease-associated pathways
In simple terms: When this process goes wrong, it can contribute to disease.
Dysregulated tyrosine phosphorylation is linked to cancer, cardiovascular disease, stroke, and dementia through proteomic and genetic evidence. Bioinformatics and Mendelian randomization studies have highlighted specific genes such as FGF5 and FAT4 in these disease contexts.
Key Genes Involved in GO:0018108 peptidyl-tyrosine phosphorylation
The following genes and proteins are representative participants or regulators of peptidyl-tyrosine phosphorylation and have been studied in real disease and developmental contexts.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FGF5 | Fibroblast growth factor ligand that activates receptor tyrosine kinase signaling | Associated with stroke risk in Mendelian randomization and bioinformatics analyses |
| PTPN1 | Protein tyrosine phosphatase that removes phosphate from tyrosine residues | Regulates testicular development and spermatogenesis in mouse models |
| FAT4 | Atypical cadherin linked to tyrosine phosphorylation-related signaling | Pan-cancer analysis identifies it as a tumor-associated gene |
| EGFR | Receptor tyrosine kinase that autophosphorylates on tyrosine | Central to cancer signaling and targeted therapy |
| SRC | Non-receptor tyrosine kinase | Proto-oncogene involved in proliferation and migration |
| STAT3 | Transcription factor activated by tyrosine phosphorylation | Drives oncogenic transcription in multiple cancers |
| PIK3CA | Kinase in the PI3K pathway downstream of tyrosine phosphorylation | Frequently mutated in cancer |
| AKT1 | Serine/threonine kinase activated by phosphotyrosine signaling | Promotes survival and growth in cancer |
| MAPK1 | Mitogen-activated protein kinase downstream of tyrosine kinases | Transmits proliferative signals |
| PTEN | Lipid phosphatase that antagonizes PI3K signaling | Tumor suppressor linked to tyrosine phosphorylation networks |
| JAK2 | Tyrosine kinase that phosphorylates STAT proteins | Driver of myeloproliferative neoplasms |
| ABL1 | Non-receptor tyrosine kinase | Target of imatinib in leukemia |
| VEGFA | Growth factor upstream of receptor tyrosine kinases | Angiogenesis and cancer progression |
| MET | Receptor tyrosine kinase | Oncogenic driver in multiple tumors |
| ALK | Receptor tyrosine kinase | Fusion oncogene in lung cancer and lymphoma |
| RET | Receptor tyrosine kinase | Driver in thyroid cancer and developmental disorders |
| NTRK1 | Neurotrophic receptor tyrosine kinase | Fusion target in solid tumors |
How Is peptidyl-tyrosine phosphorylation Regulated?
Peptidyl-tyrosine phosphorylation is regulated by the opposing activities of protein tyrosine kinases and protein tyrosine phosphatases. Receptor tyrosine kinases are activated by ligand binding and autophosphorylation, while phosphatases such as PTPN1 dephosphorylate substrates to terminate signaling. Additional layers of control include subcellular localization, scaffold proteins, and feedback loops that modulate pathway output. In disease, genetic alterations in these regulators can shift the balance toward constitutive phosphorylation, as seen in cancer and metabolic disorders.
peptidyl-tyrosine phosphorylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FGF5 | Stroke risk | Knockout or overexpression in vascular cells |
| PTPN1 | Testicular development and spermatogenesis | Knockout mouse and spermatogonial stem cell models |
| FAT4 | Pan-cancer tumorigenesis | Knockout and knock-in in cancer cell lines |
| EGFR | Cancer proliferation | Point-mutation and overexpression models |
| STAT3 | Oncogenic transcription | Knockout and phospho-mutant knock-in |
Cancer
Dysregulated peptidyl-tyrosine phosphorylation is a hallmark of many cancers, where activating mutations or amplifications of tyrosine kinases drive uncontrolled proliferation. Bioinformatics analyses of bladder cancer and pan-cancer datasets have identified tyrosine-phosphorylation-related genes as key biomarkers and potential therapeutic targets. Targeting these pathways with kinase inhibitors is a major clinical strategy.
Cardiovascular and cerebrovascular disease
Plasma proteomic biomarkers linked to tyrosine phosphorylation are associated with poor cardiovascular health and incident dementia in the UK Biobank study. Mendelian randomization and bioinformatics analyses have implicated FGF5, a ligand for receptor tyrosine kinases, in stroke risk. These findings suggest that tyrosine phosphorylation pathways contribute to vascular and neurological outcomes.
Neurodegeneration and dementia
Proteomic signatures related to tyrosine phosphorylation have been associated with incident dementia, supporting a role for these signaling events in neurodegeneration. Although the mechanisms remain under investigation, the association highlights the importance of phosphotyrosine signaling in brain health.
Developmental and reproductive biology
PTPN1, a tyrosine phosphatase, regulates testicular development and spermatogenesis in mouse models, demonstrating that tyrosine phosphorylation is essential for normal reproductive physiology. Disruption of this process can lead to developmental defects.
From peptidyl-tyrosine phosphorylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a tyrosine kinase required for tumor growth? | CRISPR knockout in cancer cell lines |
| Does a specific tyrosine residue drive signaling? | Point mutation of the tyrosine to phenylalanine |
| Can a phosphomimetic rescue the phenotype? | Knock-in of a phosphomimetic variant |
| Where is the protein localized? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression mimic disease? | Overexpression of wild-type or mutant kinase |
| Which pathways depend on the phosphatase? | Knockout of PTPN1 in relevant cell types |
How to Study the peptidyl-tyrosine phosphorylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Bioinformatics analysis | Gene expression and mutation patterns | Biomarker discovery in cancer |
| Mendelian randomization | Causal effect of genetic variants | Stroke risk assessment |
| Proteomics | Protein abundance and modifications | Plasma biomarker discovery |
| Phosphoproteomics | Site-specific phosphorylation | Mapping tyrosine phosphorylation events |
| CRISPR knockout | Loss-of-function phenotype | Testing gene necessity |
| Point mutation | Effect of specific residue change | Dissecting phosphotyrosine function |
| Knock-in | Effect of precise genetic alteration | Modeling disease variants |
Bioinformatics and multi-omics analysis
Bioinformatics pipelines integrating transcriptomic and proteomic data identify tyrosine-phosphorylation-related genes as biomarkers in cancer and other diseases. These analyses prioritize candidate genes for functional validation.
Mendelian randomization and genetic epidemiology
Mendelian randomization uses genetic variants as instruments to infer causal relationships between tyrosine phosphorylation pathway genes and disease outcomes such as stroke. This approach strengthens causal inference beyond observational associations.
Proteomics and phosphoproteomics
Plasma proteomic profiling has linked tyrosine-phosphorylation-related proteins to cardiovascular health and dementia, demonstrating the utility of large-scale proteomics for biomarker discovery. Phosphoproteomics can map specific tyrosine phosphorylation sites.
CRISPR functional genomics
CRISPR knockout, point-mutation, knock-in, and overexpression models allow direct testing of gene function in tyrosine phosphorylation pathways. These models are essential for validating bioinformatics and genetic findings.
How CRISPR Can Be Used to Study GO:0018108 peptidyl-tyrosine phosphorylation
Knockout
CRISPR knockout of tyrosine kinase or phosphatase genes enables loss-of-function studies to determine whether a gene is required for a specific signaling output or disease phenotype. For example, knocking out PTPN1 can reveal its role in developmental processes.
Point Mutation
Point mutation of a tyrosine residue to phenylalanine prevents phosphorylation at that site, allowing researchers to test the functional importance of individual phosphotyrosine events. This approach is widely used to dissect kinase substrate specificity.
Knock-in
Knock-in of phosphomimetic or disease-associated variants provides a precise model to study how specific tyrosine phosphorylation changes affect cell behavior and disease progression. This is particularly useful for validating variants identified in cancer genomics.
Overexpression
Overexpression of wild-type or mutant tyrosine kinases can mimic oncogenic signaling and is used to study pathway activation and drug response. Overexpression models complement knockout studies by revealing gain-of-function effects.
How EDITGENE Supports peptidyl-tyrosine phosphorylation Research
Researchers studying peptidyl-tyrosine phosphorylation-related genes often need to determine whether a candidate gene is causally involved in a disease or signaling pathway. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for peptidyl-tyrosine phosphorylation research.
Frequently Asked Questions About peptidyl-tyrosine phosphorylation
What is peptidyl-tyrosine phosphorylation?
Peptidyl-tyrosine phosphorylation (GO:0018108) is the covalent addition of a phosphate group to a tyrosine residue in a protein, forming peptidyl-O4'-phospho-L-tyrosine, a key signal transduction modification.
What genes are involved in peptidyl-tyrosine phosphorylation?
Genes include tyrosine kinases such as EGFR, SRC, JAK2, and ABL1, and phosphatases such as PTPN1, as well as downstream effectors like STAT3 and AKT1.
How is peptidyl-tyrosine phosphorylation regulated?
It is regulated by the balance between protein tyrosine kinases, which add phosphate, and protein tyrosine phosphatases, which remove it.
What diseases are associated with peptidyl-tyrosine phosphorylation?
It is associated with cancer, cardiovascular disease, stroke, dementia, and developmental disorders.
What is the role of PTPN1 in tyrosine phosphorylation?
PTPN1 is a protein tyrosine phosphatase that removes phosphate from tyrosine residues and regulates testicular development and spermatogenesis in mouse models.
How is FGF5 related to stroke?
Mendelian randomization and bioinformatics analyses have associated FGF5, a ligand for receptor tyrosine kinases, with stroke risk.
What methods are used to study peptidyl-tyrosine phosphorylation?
Methods include bioinformatics, Mendelian randomization, proteomics, phosphoproteomics, and CRISPR knockout, point-mutation, knock-in, and overexpression models.
Can CRISPR be used to study tyrosine phosphorylation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression are widely used to test the function of tyrosine phosphorylation genes.
What is the GO ID for peptidyl-tyrosine phosphorylation?
The Gene Ontology ID is GO:0018108, under the biological_process aspect.
Why is peptidyl-tyrosine phosphorylation important in cancer?
Dysregulated tyrosine phosphorylation drives uncontrolled proliferation and survival, making it a major target for cancer therapy.
Conclusion
Peptidyl-tyrosine phosphorylation (GO:0018108) is a central post-translational modification that governs intracellular signaling and is implicated in cancer, cardiovascular disease, stroke, and dementia. The process is controlled by the opposing actions of tyrosine kinases and phosphatases, and its dysregulation is a common theme in human disease. Advances in bioinformatics, proteomics, and CRISPR functional genomics now allow researchers to map and manipulate this pathway with unprecedented precision. EDITGENE provides the tools needed to translate these insights into causal biology and therapeutic discovery.
References
- 1. Beydoun MA et al.. 2024. Plasma proteomic biomarkers and the association between poor cardiovascular health and incident dementia: The UK Biobank study.. Brain Behav Immun 119:995-1007 PMID: 38710337
- 2. Xu C et al.. 2025. Metabolism-Mediated FGF5 Association with Stroke: Based on Mendelian Randomization and Bioinformatics Analysis.. J Multidiscip Healthc 18:4481-4495 PMID: 40765733
- 3. Liu W et al.. 2023. Bioinformatics analysis of key biomarkers for bladder cancer.. Biomed Rep 18(2):14 PMID: 36643693
- 4. Mao W et al.. 2022. A pan-cancer analysis of FAT atypical cadherin 4 (FAT4) in human tumors.. Front Public Health 10:969070 PMID: 36051999
- 5. Xue J et al.. 2019. Identification of core differentially methylated genes in glioma.. Oncol Lett 18(6):6033-6045 PMID: 31788078
- 8. Luo L et al.. 2024. miR-124-3p regulates the involvement of Ptpn1 in testicular development and spermatogenesis in mouse.. Gene 893:147967 PMID: 37931856
